EcoDrugPlus

Cell Division Cycle 7

Ensembl ID : ENSXETG00000023034
Gene Symbol: CDC7
5 View Cross-references
208 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Checkpoint Kinase 1

Ensembl ID : ENSXETG00000014861
Gene Symbol: CHEK1
5 View Cross-references
177 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Checkpoint Kinase 2

Ensembl ID : ENSXETG00000021608
Gene Symbol: CHEK2
5 View Cross-references
205 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Chemokine (C-C Motif) Receptor 2

Ensembl ID : ENSXETG00000038447
Gene Symbol: CCR2
8 Enzyme and pathways 5 View Cross-references
639 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholecystokinin A Receptor

Ensembl ID : ENSXETG00000000911
Gene Symbol: CCKAR
5 View Cross-references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholesteryl Ester Transfer Protein

Ensembl ID : ENSXETG00000034738
Gene Symbol: CETP
4 Enzyme and pathways 5 View Cross-references
137 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSXETG00000003846
Gene Symbol: CHRNB2
5 View Cross-references
197 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholinergic Receptor, Muscarinic 1

Ensembl ID : ENSXETG00000037602
Gene Symbol: CHRM1
8 Enzyme and pathways 5 View Cross-references
101 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholinergic Receptor, Muscarinic 2

Ensembl ID : ENSXETG00000049444
Gene Symbol: CHRM2
12 Enzyme and pathways 5 View Cross-references
259 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholinergic Receptor, Muscarinic 3

Ensembl ID : ENSXETG00000016229
Gene Symbol: CHRM3
8 Enzyme and pathways 5 View Cross-references
255 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholinergic Receptor, Muscarinic 4

Ensembl ID : ENSXETG00000046229
Gene Symbol: CHRM4
8 Enzyme and pathways 5 View Cross-references
184 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Cholinergic Receptor, Muscarinic 5

Ensembl ID : ENSXETG00000017868
Gene Symbol: CHRM5
8 Enzyme and pathways 5 View Cross-references
263 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).